Patent intelligence · US
US 11472889
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
Patent details — US 11472889
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 18, 2022
- Expiration
- Oct 13, 2042
- Applicant
- CytomX Therapeutics, Inc.
- Claims
- 18
- CPC classes
- A61K, A61K2039/505, A61P, A61P35/00
Quick answer
US 11472889 (Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof) is held by CytomX Therapeutics, Inc.. Status: granted. Granted Oct 18, 2022. Expires Oct 13, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CytomX Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K2039/505, A61P, A61P35/00
More from CytomX Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12428470
Compositions containing activatable antibodies
granted -
US 12139543
Method of using an anti-epidermal growth factor receptor (EGFR) activatable antibody to detect the presence or absence of a cleaving agent and EGFR
granted -
US 12049505
Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
granted -
US 11992528
Compositions and methods for conjugating activatable antibodies
granted -
US 11952427
Anti-CD40 antibodies and uses thereof
granted -
US 11890354
Activatable antibodies that bind epidermal growth factor receptor and methods thereof
granted -
US 11884746
Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
granted -
US 11867695
Compositions and methods for detecting protease activity in biological systems
granted
Frequently asked questions
What is US patent 11472889?
US 11472889 (Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof) is held by CytomX Therapeutics, Inc.. Status: granted. Granted Oct 18, 2022. Expires Oct 13, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11472889?
CytomX Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 62 pharmaceutical patents for this assignee.
When does US 11472889 expire?
Our index shows an expiration date of Oct 13, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.